Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.

By S. Nicholls, R. Puri, T. Anderson, Christie M. Ballantyne, L. Cho, J. Kastelein, W. Koenig, R. Somaratne, H. Kassahun, Jingyuan Yang and 9 more. Journal of the American Medical Association (JAMA), 2016

1,077 citations recorded by the source corpus.

Subfields: Immunology, Surgery

View Paper: https://www.semanticscholar.org/paper/db059bffb9744e908a947ad803b43830e93ba4e1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Alberico L. Catapano

In Surgery

1. Jan Boren
2. I. Graham
3. Marja-Riitta Taskinen
4. Jay D. Horton
5. Alberico L. Catapano
6. Ulrich Laufs
7. Ronald M. Krauss

Citations in the corpus

• Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel (2017, result): “6 mg/ dl).(44) Taken together, the results of these studies strongly suggest that PCSK9 inhibitors and statins have biologically equivalent effects on the risk of cardiovascular events per unit change in LDL-C.”